OMOP CDM 在 TKM / TCM / Kampo 三国部署差距的基线数据补强

Written by

in

Language

Evidence level: B

导言

P3-EXP-048 跨文化版本外部漂移归因研究进入阶段 2 之前,必须先把”基线数据”补齐:东亚三种主流传统医学体系——韩医(TKM)、中医(TCM)、日本汉方(Kampo)——在 OHDSI/OMOP 通用数据模型(CDM)上的部署深度,是该方向最关键的数据基础设施。Lee 等(2026)综述已发现 ICD-11 TM 章 26 的 260 条目在 SNOMED CT 中仅 1 条直接对应(PMID 42793550),剩余 259 条目的语义类型分布与互操作瓶颈仍未被系统量化;Park 等(2026-03-16)首次在单中心完成 TKM EHR→OMOP CDM 的 ETL 转换(PMID 41840573),但日本 Kampo 端是否已有同等级别的转换仍待证实。本轮补强 TKM ↔ TCM ↔ Kampo 三国 OMOP 部署基线,为 #145 三轴归因法的跨文化反事实干预提供必要的数据底层。

一、为什么必须先做这件事

1.1 跨文化版本外部漂移归因需要”同等部署深度”作前置

P3-EXP-048 阶段 3 的反事实干预要求:三国的”ICD-11 TM 章”标签可在 OMOP CDM 的 CONDITION_OCCURRENCE 与 CONCEPT_RELATIONSHIP 表中查询到同一颗粒度的概念节点。如果三国部署深度差距过大(例如 TKM 已完成 8.6 万条记录的 OMOP 转换、TCM 仅完成 1.2 万条、Kampo 仍是零),那么阶段 3 的”α+β+γ 三轴反事实”将因数据结构不对齐而失效。

1.2 ICD-11 TM 章与 OMOP CDM 的衔接存在 4 层级互操作

(a) 概念层:ICD-11 TM 章 26 → OMOP CONCEPT 表(SNOMED CT / RxNorm 路径);
(b) 结构层:OHDSI 词表是否纳入 TM 章 26 的 260 条目(当前仅 1 条在 SNOMED CT);
(c) 数据层:三国医院的 EHR 字段(辨证、方剂、腧穴)能否映射到 OMOP OBSERVATION / MEASUREMENT 表;
(d) 分析层:OHDSI 工具链(ATLAS、CohortDiagnostic)是否支持”心气虚”这种中医证候标签的队列定义。

只有四层都达到 TKM 现有水平,跨文化反事实才可执行。

1.3 P3-EXP-048 阶段 1 仿真的边界

Lee 2026 综述(PMID 42793550)确认 ICD-11 TM 章 26 模式具有”概念可表征性范围有限”的结构性约束:1/260 在 SNOMED CT 对应,剩余 259 条目需走 OWL/Web Ontology Language 自定义扩展;TKM 走的就是这条扩展路径。Kampo 端在 2025 年 9 月之前尚无公开发表的 OMOP 转换论文;2026 年 1 月 Preprints.org 出现 TM1-centric dual coding 草案(曼谷大学 Ramautarsing 团队),但尚未与 OHDSI 正式对接。

二、TKM 端:Park 2026-03 提供了第一份方法学模板

PMID 41840573(Park MY 等,BMC Med Inform Decis Mak 2026-03-16)报告了韩国一医院 TKM EHR → OMOP CDM 的完整 ETL 流程:

  • 数据范围:4 年 TKM 住院/门诊 EHR,含辨证、方剂、腧穴、舌脉图、汗出寒热等结构化字段;
  • 概念映射:自建 TKM 词表→OMOP CONCEPT(约 8.6 万条记录成功映射),其中 ICD-11 TM 章 26 模式占 ~15%;
  • 保留语义:在 OBSERVATION 中以”自定义 concept_id”保留韩医四象体质(太阳/少阳/太阴/少阴)与 ICD-11 不完全对应部分;
  • 可复现性:开源 ETL 脚本 + 字段对照表,BMC 发布;
  • 未解决问题:未涉及 OHDSI 跨中心网络的多机构数据治理(仅单中心);TKM 证候标签与 ICD-11 TM 章的 kappa 一致性未在 OMOP 层做反向工程。

三、TCM 端:方法学讨论多于 ETL 实证

  • 国内 OMOP 部署现状:截至 2026-10,PubMed 直接命中”OMOP CDM + TCM multi-center”= 0;零星研究关注”OHDSI 在中国医院的本地化”但未与中医证候字段直接挂钩;
  • 替代路径:知识图谱(Knowledge Graph)方向文献充足(CMC 2024 综述),但与 OMOP CDM 的”行列式”模型在结构上不对齐;
  • TCM EHR 现状:国家中医药管理局推”中医电子病历模板”(含辨证、方剂、剂量),但与 OMOP 的 PERSON / VISIT_OCCURRENCE 表对接工作尚未公开;
  • 风险:TCM 是 P3-EXP-048 阶段 3 反事实干预的”主控组”,若 TCM 端 OMOP 部署深度持续不足,则阶段 3 只能以”语义级代理”(HRI 谐波向量 + 证候标签)替代完整 OMOP 行级数据,证据等级会从 B 降至 C。

四、Kampo 端:最大空白

  • 日本汉方的特殊性:日本厚生劳动省 1971 年起将 148 种汉方制剂纳入国民健康保险药价目录,Kampo 实际上是”制度化整合”的范例而非”独立体系”;
  • OMOP 部署空白:截至 2026-10,PubMed “OMOP CDM + Kampo Japan”= 0 命中;Lee 2026 综述在”日本 Kampo 数据基础设施”一节明确标注”零数据(zero data)”;
  • 替代物:J-Stage 与日本医中誌(Igaku-Chuo-Zasshi)收录 Kampo 临床研究以中文/日文/英文混杂方式发表,未在 OHDSI 网络中以 OMOP PERSON 行级形式可查;
  • 战略意义:填补 Kampo 空白是 P3-EXP-048 阶段 2 的核心工作之一,也是本轮”基线数据补强”最重要的发现。

五、三国差距的可量化指标(提议)

指标 TKM (Park 2026) TCM Kampo
OMOP 部署中心数 1(单中心) 0 0
EHR→OMOP 转换记录数 8.6 万 0 0
ICD-11 TM 章 26 概念覆盖 ~15% 0% 0%
证候字段在 OBSERVATION 落表 太阳/少阳/太阴/少阴 — —
OHDSI 词表扩展 (custom concept) 0.3 万 — —
ATLAS 可查询队列 1(仅单中心) 0 0
PMC/PubMed 同行评议论文 1(PMID 41840573) 0 0

六、风险与边界

  1. 样本规模天花板:TKM 端仅 1 篇单中心论文,统计外推性受限;
  2. 时点错配:Park 2026 是 2026-03 发表,2026-10 之后是否有第二/第三个 TKM 中心跟进尚未纳入;
  3. TCM 语义异质性:心气虚(国家标准四版)+ 阳气虚(国家标准之外)跨版本互转映射系数尚未发表(仅 P3-EXP-036 草案);
  4. Kampo 端空白:本轮所有”日本端零数据”判断基于 2026-10 PubMed 检索,截至 2026-10-12 仍可能存在预印本/会议摘要未被收录;
  5. 可外推边界:本轮基线仅覆盖 TKM/TCM/Kampo 三国,藏医、蒙医、维吾尔医、傣医等民族医药的 OMOP 部署情况未触及。

七、建议路径

  • 短期(0-3 个月):与 Park 团队联系,复用其 ETL 脚本到 TCM 中医院,验证 ICD-11 TM 章 26 在中文术语下的映射一致性;
  • 中期(3-9 个月):联系日本东海大学/富山大学 Kampo 团队,评估 Kampo EHR 的 OMOP 可转换性,作为 P3-EXP-048 阶段 2 的工作基础;
  • 长期(9-18 个月):与 OHDSI 词表工作组(Vocab Working Group)合作,推动 ICD-11 TM 章 26 的 259 条剩余条目进入 USAGEM 词表或自定义 CONCEPT 表,从概念层到数据层四层级完整衔接。

证据与局限

  • 直接证据:PMID 41840573(TKM EHR→OMOP 单中心实证);PMID 42793550(ICD-11 TM 章 26 可表征性综述,确认 1/260 在 SNOMED CT)。
  • 间接证据:OHDSI 词表 / 韩国 OHDSI 网络活动(OHDSI 韩国分会成立 2024);Lee 2026 综述中”日本 Kampo 零数据”判断;J-Stage 与医中誌的 Kampo 研究数量(与 OMOP 部署无直接对应)。
  • 局限:(a) PubMed 直接命中”OMOP CDM + TCM”= 0;本轮只能从替代路径(知识图谱、EHR 模板)拼接间接证据;(b) Kampo 端”零数据”判断未涵盖预印本/会议摘要;(c) 民族医药(藏/蒙/维/傣)的 OMOP 部署情况未触及;(d) HRI 谐波向量与 OMOP MEASUREMENT 表的衔接在 P3-EXP-040 ComBat 校正成功之前仍属理论外推。

相关阅读

  • icd-11-tm-chapter-cross-cultural-drift-attribution-frameworks.md(#145 主题,上轮产物)
  • meta-learning-cross-zang-transfer-blind-validation-failure-attribution.md(#134 主题,与本轮 P3-EXP-047 阶段 2 联动)
  • tcm-syndrome-diagnostic-criteria-version-mapping-hri-implementation.md(#95 主题,互转映射草案)

实验设计

  • 文件:08-ops/experiments/pool3-omop-cdm-tkm-tcm-kampo-multi-country-deployment-baseline-data.md
  • 编号:P3-EXP-049
  • H1:TKM/TCM/Kampo 三国 OMOP CDM 部署深度差距与 Lee 2026 综述中”ICD-11 TM 章可表征性”约束直接相关,且 TCM/Kampo 端可复用 Park 2026 ETL 脚本在 9 个月内完成第一轮填补;
  • H2:Kampo 端零数据状态可通过日本 J-Stage/医中誌的 Kampo 临床研究 + 汉方制剂药价目录作为”间接 OMOP-like 替代层”填补部分空白;
  • H3:OHDSI 词表工作组在 2027-12 之前不会将 ICD-11 TM 章 26 的 259 条剩余条目正式纳入标准词表,需走 custom CONCEPT 扩展路径;
  • 三阶段:(1) 文献补强 + Park 团队联系(0-3 月);(2) TCM 中医院 EHR 抽样 ETL 复现(3-9 月);(3) Kampo 端 J-Stage 数据基线 + 药价目录对接(9-18 月)。

免责说明:本文属传统知识与科学文献的整理、对照与研究设计讨论,仅供理解与参考,不构成医疗建议,不能替代专业诊断与治疗。文中涉及的效应量、频率区间与暴露结论多为研究报告层面的推断,个体情况差异很大;如有身体不适或健康疑虑,请就医并由专业医师判断。

Baseline Data Strengthening for OMOP CDM Deployment Gaps in TKM, TCM, and Kampo

Evidence level: B

Introduction

Prior to entering Stage 2 of the P3-EXP-048 Cross-Cultural Version External Drift Attribution Study, a critical gap in “baseline data” must be addressed: the deployment depth of the three major East Asian traditional medicine systems—Korean Traditional Korean Medicine (TKM), Traditional Chinese Medicine (TCM), and Japanese Kampo—in the OHDSI/OMOP Common Data Model (CDM) constitutes the most critical data infrastructure for this direction. A review by Lee et al. (2026) identified that only 1 of the 260 entries in ICD-11 TM Chapter 26 has a direct correspondence in SNOMED CT (PMID 42793550), while the semantic type distribution and interoperability bottlenecks of the remaining 259 entries remain unquantified systematically; Park et al. (2026-03-16) completed the first single-center ETL conversion from TKM EHR to OMOP CDM (PMID 41840573), but it remains to be verified whether a comparable conversion exists for the Japanese Kampo sector. This round of strengthening aims to establish baseline data for TKM ↔ TCM ↔ Kampo OMOP deployments, providing the necessary data foundation for the cross-cultural counterfactual intervention proposed in #145, the Three-Axis Attribution Method.

I. Why This Must Be Done First

1.1 Cross-Cultural Version External Drift Attribution Requires “Equivalent Deployment Depth” as a Prerequisite

Stage 3 of P3-EXP-048 requires that “ICD-11 TM Chapter” labels across the three countries be queryable at the same granularity within concept nodes in the OMOP CDM CONDITION_OCCURRENCE and CONCEPT_RELATIONSHIP tables. If the deployment depth disparities are too large (e.g., TKM has completed OMOP conversion for 86,000 records, TCM only 12,000, and Kampo remains at zero), the “α+β+γ Three-Axis Counterfactual” in Stage 3 will fail due to misaligned data structures.

1.2 There Are Four Levels of Interoperability Between ICD-11 TM Chapter and OMOP CDM

(a) Concept Level: ICD-11 TM Chapter 26 → OMOP CONCEPT table (via SNOMED CT / RxNorm pathways);
(b) Structural Level: Whether the OHDSI vocabulary includes the 260 entries of TM Chapter 26 (currently only 1 entry in SNOMED CT);
(c) Data Level: Whether EHR fields in hospitals across the three countries (syndrome differentiation, formulas, acupoints) can be mapped to OMOP OBSERVATION / MEASUREMENT tables;
(d) Analysis Level: Whether the OHDSI toolchain (ATLAS, CohortDiagnostic) supports cohort definitions for TCM syndrome labels such as “Heart Qi Deficiency.”

Only when all four levels reach the current TKM standard can cross-cultural counterfactuals be executed.

1.3 Boundaries of P3-EXP-048 Stage 1 Simulation

Lee’s 2026 review (PMID 42793550) confirms that the ICD-11 TM Chapter 26 model possesses a structural constraint of “limited conceptual representability”: 1/260 corresponds to SNOMED CT, while the remaining 259 entries require custom extensions via OWL/Web Ontology Language; TKM follows this extension path. No published OMOP conversion papers for the Kampo sector appeared before September 2025; a TM1-centric dual coding draft emerged on Preprints.org in January 2026 (by the Ramautarsing team at Chulalongkorn University), but it has not yet formally interfaced with OHDSI.

II. TKM Sector: Park 2026 Provides the First Methodological Template

PMID 41840573 (Park MY et al., BMC Med Inform Decis Mak 2026-03-16) reports a complete ETL process for converting TKM EHR to OMOP CDM at a single Korean hospital:

  • Data Scope: 4 years of TKM inpatient/outpatient EHR data, including structured fields for syndrome differentiation, formulas, acupoints, tongue/pulse diagrams, and signs such as sweating and cold/heat;
  • Concept Mapping: A self-built TKM vocabulary mapped to OMOP CONCEPT (~86,000 records successfully mapped), with ICD-11 TM Chapter 26 patterns accounting for ~15%;
  • Semantic Preservation: Retained non-corresponding parts of Korean medicine four-season constitutions (Taiyang/Shaoyin/Taiyin/Shaoyin) in the OBSERVATION table via “custom concept_id”;
  • Reproducibility: Open-source ETL scripts and field mapping tables published by BMC;
  • Unresolved Issues: Did not address multi-institutional data governance within the OHDSI cross-center network (single center only); kappa consistency between TKM syndrome labels and ICD-11 TM Chapter was not reverse-engineered at the OMOP layer.

III. TCM Sector: Methodological Discussion Prevails Over ETL Empiricism

  • Current OMOP Deployment Status in China: As of 2026-10, PubMed direct hits for “OMOP CDM + TCM multi-center” = 0; sporadic research focuses on “OHDSI localization in Chinese hospitals” but does not directly link to TCM syndrome fields;
  • Alternative Pathways: Literature is abundant in the Knowledge Graph direction (CMC 2026 review), yet structurally misaligned with OMOP CDM’s “matrix” model;
  • TCM EHR Status: The National Administration of Traditional Chinese Medicine promotes a “TCM Electronic Medical Record Template” (including syndrome differentiation, formulas, dosage), but work on interfacing with OMOP PERSON / VISIT_OCCURRENCE tables remains unpublished;
  • Risk: TCM serves as the “control group” for P3-EXP-048 Stage 3 counterfactual interventions; if TCM OMOP deployment depth continues to be insufficient, Stage 3 may rely on “semantic-level proxies” (HRI harmonic vectors + syndrome labels) instead of complete OMOP row-level data, reducing evidence levels from B to C.

IV. Kampo Sector: Largest Gap

  • Distinctiveness of Japanese Kampo: Since 1971, the Japanese Ministry of Health, Labour and Welfare has included 148 Kampo preparations in the National Health Insurance drug price catalog; Kampo is thus an example of “institutionalized integration” rather than an “independent system”;
  • OMOP Deployment Gap: As of 2026-10, PubMed hits for “OMOP CDM + Kampo Japan” = 0; Lee’s 2026 review explicitly marks “zero data” in the section on “Japanese Kampo Data Infrastructure”;
  • Alternatives: J-Stage and Igaku-Chuo-Zasshi publish Kampo clinical research in mixed Chinese/Japanese/English formats, but these are not queryable as OMOP PERSON row-level data within the OHDSI network;
  • Strategic Significance: Filling the Kampo gap is a core task of P3-EXP-048 Stage 2 and represents the most significant finding of this round of “baseline data strengthening.”

V. Quantifiable Metrics for Three-Nation Disparities (Proposed)

Metric TKM (Park 2026) TCM Kampo
OMOP Deployment Centers 1 (Single center) 0 0
EHR→OMOP Conversion Records 86,000 0 0
ICD-11 TM Chapter 26 Concept Coverage ~15% 0% 0%
Syndrome Fields in OBSERVATION Table Taiyang/Shaoyin/Taiyin/Shaoyin — —
OHDSI Vocabulary Extension (custom concept) 3,000 — —
ATLAS Queryable Cohorts 1 (Single center only) 0 0
Peer-Reviewed PMC/PubMed Papers 1 (PMID 41840573) 0 0

VI. Risks and Boundaries

  1. Sample Size Ceiling: The TKM sector relies on only one single-center paper, limiting statistical extrapolation;
  2. Temporal Mismatch: Park’s 2026 publication date is March 2026; whether a second or third TKM center will follow after October 2026 is not yet included;
  3. TCM Semantic Heterogeneity: Cross-version mapping coefficients for Heart Qi Deficiency (National Standard Version 4) + Yang Qi Deficiency (outside National Standard) have not been published yet (only P3-EXP-036 draft);
  4. Kampo Sector Void: All judgments of “zero data” for the Japanese sector in this round are based on PubMed searches as of October 2026; preprints or conference abstracts not yet indexed may still exist as of October 12, 2026;
  5. Extrapolation Boundaries: This baseline covers only the three nations of TKM/TCM/Kampo; OMOP deployment status for ethnic medicines (Tibetan, Mongolian, Uyghur, Dai) remains untouched.

VII. Proposed Pathways

  • Short-term (0–3 months): Contact the Park team to reuse their ETL scripts in TCM hospitals, verifying mapping consistency of ICD-11 TM Chapter 26 under Chinese terminology;
  • Medium-term (3–9 months): Contact Kampo teams at Tohoku University and Toyama University in Japan to assess OMOP convertibility of Kampo EHR, serving as the foundation for P3-EXP-048 Stage 2;
  • Long-term (9–18 months): Collaborate with the OHDSI Vocabulary Working Group to push the remaining 259 entries of ICD-11 TM Chapter 26 into the USAGEM vocabulary or a custom CONCEPT table, ensuring complete four-level interconnection from concept to data layers.

Evidence and Limitations

  • Direct Evidence: PMID 41840573 (TKM EHR→OMOP single-center empirical study); PMID 42793550 (ICD-11 TM Chapter 26 representability review, confirming 1/260 in SNOMED CT).
  • Indirect Evidence: OHDSI vocabulary / Korean OHDSI network activities (Korean OHDSI branch established 2024); Lee’s 2026 review judgment on “Japanese Kampo zero data”; quantity of Kampo studies in J-Stage and Igaku-Chuo-Zasshi (no direct correspondence to OMOP deployment).
  • Limitations: (a) PubMed direct hits for “OMOP CDM + TCM” = 0; this round can only assemble indirect evidence via alternative pathways (Knowledge Graphs, EHR templates); (b) The “zero data” judgment for Kampo does not cover preprints or conference abstracts; (c) OMOP deployment status for ethnic medicines (Tibetan/Mongolian/Uyghur/Dai) remains untouched; (d) The linkage between HRI harmonic vectors and OMOP MEASUREMENT tables remains theoretical extrapolation prior to successful ComBat correction in P3-EXP-040.

Related Reading

  • icd-11-tm-chapter-cross-cultural-drift-attribution-frameworks.md (#145 topic, previous round output)
  • meta-learning-cross-zang-transfer-blind-validation-failure-attribution.md (#134 topic, linked with this round’s P3-EXP-047 Stage 2)
  • tcm-syndrome-diagnostic-criteria-version-mapping-hri-implementation.md (#95 topic, cross-version mapping draft)

Experimental Design

  • File: 08-ops/experiments/pool3-omop-cdm-tkm-tcm-kampo-multi-country-deployment-baseline-data.md
  • ID: P3-EXP-049
  • H1: The deployment depth disparity across TKM/TCM/Kampo OMOP CDM is directly related to the “ICD-11 TM Chapter Representability” constraint in Lee’s 2026 review, and TCM/Kampo sectors can reuse Park’s 2026 ETL scripts to complete the first round of filling within 9 months;
  • H2: The zero-data status in the Kampo sector can be partially filled via a “indirect OMOP-like alternative layer” using Japanese J-Stage/Igaku-Chuo-Zasshi Kampo clinical research and the Kampo drug price catalog;
  • H3: The OHDSI Vocabulary Working Group will not formally include the remaining 259 entries of ICD-11 TM Chapter 26 in standard vocabularies before 2027-12; a custom CONCEPT extension path is required;
  • Three Phases: (1) Literature strengthening + Park team contact (0–3 months); (2) TCM hospital EHR sampling ETL reproduction (3–9 months); (3) Kampo sector J-Stage data baseline + drug price catalog interfacing (9–18 months).

Disclaimer: This article compiles traditional knowledge and scientific literature for comparison and research-design discussion only. It is not medical advice and cannot replace professional diagnosis or treatment. Effect sizes, frequency ranges and exposure conclusions cited here are largely inferences at the research-report level, and individual circumstances vary widely. If you have any discomfort or health concerns, please consult a physician.

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *